What Researchers Did
Researchers reviewed various new treatment strategies proposed for meningococcal septic shock, including immunotherapy, hemofiltration, anticoagulants, protein C, blood exchange, and local therapies.
What They Found
Immunotherapy with antiserum to Escherichia coli J5 and human antilipid A monoclonal antibodies did not significantly alter the mortality rate of meningococcal septic shock. While antithrombin concentrate was reported in only one child, and blood and plasma exchange appeared safe, the true benefits and efficacy of many new strategies, such as hemofiltration, protein C, and recombinant tissue plasminogen activator, remain unknown or require further evaluation.
What This Means for Canadian Patients
For Canadian patients with meningococcal septic shock, current standard treatments remain the primary approach, as many newer proposed strategies lack sufficient evidence for widespread adoption. Further research is needed to establish the efficacy and safety of these emerging therapies before they can be routinely integrated into clinical practice.
Canadian Relevance
This study does not have a direct Canadian connection.
Study Limitations
A significant limitation is that many of the reviewed strategies were based on anecdotal reports, small series, or studies from which firm conclusions could not be drawn.